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MPV, P-LCR after treatment and MACE events.
RESULTS 1. MPV and P-LCR, were higher in ACS group than the
control group (P < 0.05), in the control group, UA group, STEMI
and NSTEMI group showed a trend of rising (P < 0.05). 2.
Spearman correlation analysis: the MPV, P-LCR and Gensini score
were positively correlated. Multiariable Logistic regression analysis
shows MPV, P-LCR is a risk factor for the ACS.3. In the follow-up
period, there are a total of 25 cases MACE incident, including 14
cases of recurrence of angina, 8 cases of recurrence myocardial
infarction and line again revascularization, 3 cases of stent
thrombosis, 0 cases died。Follow-up results show that the MPV, P-
LCR fell more obviously in the non-MACE group, when compared
with the MACE group, the difference was statistically signiﬁcant
(P < 0.05).
CONCLUSIONS 1. The research shows that MPV and P - the LCR
elevated in patients with ACS, more obviously in patients with
myocardial infarction, prompt platelet volume change was associated
with disease severity of ACS.2. The change of MPV, P –LCR were
positively correlated with Gensini score, which can reﬂect the severity
of coronary artery lesions.3. Follow-up results showed that MPV, P -
the LCR drops more apparent in non-MACE group, prompt platelet
volume changes were associated with MACE events within six
months.GW26-e1418
Expression And Clinical Signiﬁcance of IL-25 In The Serum Of Patients With
Acute Coronary Syndrome
Dongxu Sun, Ming Zhu, Tianyi Song, Xin Sun
Beihua University
OBJECTIVES The objective of this study is to determine IL-25
expression in the serum of patients with ACS and its clinical
signiﬁcance.
METHODS Blood samples for serum detection were collected from 60
ACS patients ( including 20 STEMI, 10 NSTEMI, 11 UAP ), 20 SAP and 30
healthy volunteers from Afﬁliated Hospital of Beihua University and
Jilin Central Hospital from September, 2012 to November 12th, 2013.
The serum levels of IL-25 was measure by ELISA. They were divided
into three groups according to the number of coronary artery stenosis:
single vessel disease group, double vessel disease group and multi
vessel disease group. Recorded their general information and the data
of relevant clinical. Experimental data were processed by SPSS 17.0
statistical analysis software. A value of P <0.05 was considered sta-
tistically signiﬁcant.
RESULTS 1. The serum of IL-25 in ACS: Signiﬁcant differences in IL-25
found between ACS group and SAP group, normal group ( P<0.05);
No signiﬁcant differences in IL-25 found between SAP group and
normal group ( P>0.05 ).
2. The serum of IL-25 in different types of ACS: Signiﬁcant differ-
ences in IL-25 found between STEMI group and NSTEMI group, UAP
group ( P<0.05); No signiﬁcant differences in IL-25 found between
NSTEMI group and UAP group ( P>0.05 ).
3. There is a correlation between level of IL-25 and CRP ( r¼0.513,
P<0.05 ).
4. There is a correlation between level of IL-25 and TnI ( r¼0.432,
P<0.05 ).
5. No signiﬁcant differences in IL-25 found between coronary
vascular lesion count ( P>0.05 ).
CONCLUSIONS 1. The level of IL-25 in patients of ACS were much
higher than SAP group and normal group, special much higher in
patients of STEMI, and there is a correlation between level of CRP
and TnI, it can offer us a new idea about the development of ACS in
IL-25.
2. IL-25 as a mark can be used as serological indexes detect the
condition changes of ACS. It has a certain value to diagnosis the ACS.
3. It is the ﬁrst time found the serum level of IL-25 in patients of
ACS, the serum level of IL-25 much higher in patients of ACS, and
there is a correlation between level of CRP and TnI, but no signiﬁcant
differences in IL-25 found between coronary vascular lesion count, so
it can be a mark to diagnosis the ACS.
4. This study demonstrated that the serum level of IL-25 much
higher in patients of inﬂammatory diseases like Lung infection,Asthma, Intestinal inﬂammation and so on. But we cannot ﬁnd the
relationship between IL-25 and ACS. So this study takes a new way of
mechanism and relationship on inﬂammation and ACS.
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OBJECTIVES The overall risk–beneﬁt proﬁle of new generation oral
anticoagulants (NOAC) in addition to antiplatelet therapy on hemor-
rhagic as well as ischemic stroke for patients with acute coronary
syndrome (ACS) has not been clearly established.
METHODS Studies evaluating clinical outcomes of NOAC (including
direct Xa inhibitors, direct thrombin inhibitors and PAR-1 antagonists)
in addition to standard antiplatelet therapy in patients with recent
ACS, published before Nov 2014, were screen. Eleven double blind,
placebo-controlled, randomized clinical studies including 46782 pa-
tients were identiﬁed.
RESULTS The study revealed a 3-fold increased risk of hemorrhagic
stroke in patients receiving NOAC in addition to antiplatelet therapy
compared to those without NOAC (OR 3.04, 95% CI 1.77 to 5.25,
P <0.0001). There was also a signiﬁcantly increased risk of major
bleeding in patients receiving NOAC (OR 2.45, 95% CI 1.58 to 3.80,
P <0.0001). However, the use of NOAC was associated with a signiﬁ-
cantly reduced risk of ischemic stroke (OR 0.79, 95% CI 0.64 to 0.99,
P ¼0.04) and composite efﬁcacy outcome (death/myocardial infarc-
tion/stroke) (OR 0.87, 95% CI 0.81 to 0.93, P <0.0001). There was also
a borderline signiﬁcant reduction in all-cause mortality (OR 0.91, 95%
CI 0.82 to 1.00, P¼0.05) in favor of NOAC therapy.
CONCLUSIONS In patients with ACS, the addition of NOAC to an-
tiplatelet therapy led to a modest but signiﬁcant reduction in
ischemic stroke and overall composite efﬁcacy outcome at the cost
of a substantial increase in hemorrhagic stroke and major bleeding
events.
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To study involvement of serum matrix metalloproteinase-9 in
pathogenesis of myocardial infarction
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OBJECTIVES To study the involvement of serum MMP-9 enzyme in
the pathogenesis during the rupture of the coronary atherosclerosis
plaque.
METHODS The study was conducted using case-control design. The
main inclusion criteria of the case group is that the patient should
have a ruptured coronary atherosclerotic plaque, conﬁrmed by angi-
ography. The total number of patients is 80, half of them belongs to
the case group. MMP-9 is was determined in serum by ELISA. We used
CIIS (cardiac infarction injury score) by ECG and Gensini score system
(Coronary Angiographic Scoring System) for assessing the severity of
coronary heart disease.
RESULTS The average level of MMP-9 in case and control groups are
0.3960.155 ng/ml, 0.2230.087 ng/ml respectively with p<0.001
signiﬁcance which shows MMP-9 (OR¼0.001, p<0.001) may plays a
role in the pathogenesis of plaque rupture. MMP-9 is correlated with
Gensini score and CIIS score, respectively (r¼0.552, p<0.01; r¼0.340,
p<0.01) which shows MMP-9 is being elevated with the increase of the
severity of coronary heart disease and the cardiac infarction injury.
Serum MMP-9 increases statistically signiﬁcantly (p<0.001) with the
increase of the severity of the stenosis and the number of the affected
arteries: no severe stenosis (<75% stenosis) (0.2450.086 ng/ml); 1
vessel severe(>75%) stenosis (0.3170.132 ng/ml), 2 vessel severe
stenosis (0.3480.157 ng/ml), 3 vessel severe stenosis (0.4220.112
ng/ml).
Furthermore, serum MMP-9 enzyme increases with accordance of
severity of the myocardium injury with the statistical signiﬁcance
